The conduct of a clinical trial should be adequately monitored by the sponsor in order to ensure the reliability and robustness of the results. Monitoring may also contribute to subject safety, taking into account the characteristics of the clinical trial and respect for fundamental rights of subjects. When establishing the extent of monitoring, the characteristics of the clinical trial should be taken into account.
Recital 44, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…
In forcesince 16 Apr 2014